This analysis examines out-of-pocket costs on insulin among Medicare Part D enrollees between 2020 and 2024 to assess changes over time as voluntary and mandatory insulin copay limits took effect. The implementation of these measures resulted in a substantial reduction in out-of-pocket spending by enrollees without low-income subsidies who used insulin, with out-of-pocket spending on insulin decreasing from $971 million to $506 million in the aggregate between 2020 and 2024 and from $54 to $25 for each insulin prescription over the same period.
Out-of-Pocket Costs for Insulin Among People with Medicare Decreased by Half Between 2020 and 2024